Patent expiry and costs for anti-cancer medicines for clinical use : expiry and costs anti-cancer medicines

Godman, Brian and Wild, Claudia and Haycox, Alan (2017) Patent expiry and costs for anti-cancer medicines for clinical use : expiry and costs anti-cancer medicines. Generics and Biosimilars Initiative journal. pp. 1-3. ISSN 2033-6403 (In Press)

Preview

Text (Godman-etal-GABI-2017-Patent-expiry-and-costs-for-anti-cancer-medicines-for-clinical) Godman_etal_GABI_2017_Patent_expiry_and_costs_for_anti_cancer_medicines_for_clinical.pdf Accepted Author Manuscript Download (235kB)| Preview

Abstract

Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.

• Share and Export
  

  RDF+XMLBibTeXRIOXX2 XMLRDF+N-TriplesJSONDublin CoreAtomSimple MetadataReferMETSArchivematicaHTML CitationASCII CitationOpenURL ContextObjectEndNoteOpenURL ContextObject in SpanMODSMPEG-21 DIDLEP3 XMLData Cite XMLRIS (EndNote Online, Zotero, Ref manager, etc)RDF+N3Multiline CSV
• Item metadata

  Item type:	Article
  ID code:	60241
  Dates:	Date Event 17 March 2017 Published 17 March 2017 Accepted
  Keywords:	anti cancer medicines, medicine patents, tyrosine kinase inhibitors, Pharmacy and materia medica, Pharmacology, Toxicology and Pharmaceutics(all)
  Subjects:	Medicine > Pharmacy and materia medica
  Department:	Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
  Depositing user:	Pure Administrator
  Date deposited:	20 Mar 2017 10:18
  Last modified:	17 Jun 2021 00:58
  Related URLs:	Journal or Publication
  URI:	https://strathprints.strath.ac.uk/id/eprint/60241